Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations

被引：2
|
作者：
Marmarelis, Melina E. [1 ]
Langer, Corey J. [1 ]
机构：
[1] Univ Penn, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA
来源：
CLINICAL LUNG CANCER | 2020年 / 21卷 / 05期
关键词：
BRAF; MET; NTRK; RET; ROS1; GROWTH-FACTOR RECEPTOR; RANDOMIZED PHASE-II; MOLECULAR TESTING GUIDELINE; OF-AMERICAN-PATHOLOGISTS; OPEN-LABEL; SINGLE-ARM; CLINICAL CHARACTERISTICS; ROS1; REARRANGEMENTS; ACQUIRED-RESISTANCE; RET REARRANGEMENTS;
D O I：
10.1016/j.cllc.2020.01.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Non-small-cell lung cancer is a major cause of cancer morbidity and mortality worldwide, and these patients have traditionally had a grim prognosis. As our understanding of actionable molecular aberrations that drive oncogenesis has grown, so too has the number of available therapies with improved outcomes in selectively targeted patient populations. This review provides an overview of the clinical response of tumors harboring relatively rare oncogenic drivers to currently approved targeted agents and those in late-stage clinical development. Molecular testing methods available for screening for oncogenic drivers will be discussed. (C) 2020 Published by Elsevier Inc.
引用
收藏
页码：395 / 406
页数：12
相关论文
共 50 条
  • [21] Elderly patients treatment with non-small-cell lung cancer
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2012, 8 (01): : 29 - 35
  • [22] Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population
    Xu, C.
    Wang, W.
    Zhang, Q.
    Zhuang, W.
    Zhu, Y.
    Chen, Y.
    Fang, M.
    Chen, G.
    Lv, T.
    Song, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S524 - S524
  • [23] Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations
    Xu, C.
    Wang, W.
    Zhuang, W.
    Huang, Z.
    Song, Z.
    Chen, Y.
    Liu, W.
    Chen, R.
    Guan, Y.
    Yi, X.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1940 - S1940
  • [24] A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations
    Imai, Hisao
    Kaira, Kyoichi
    Suzuki, Kensuke
    Anzai, Masaki
    Tsuda, Takeshi
    Ishizuka, Tamotsu
    Kuwako, Tomohito
    Naruse, Ichiro
    Nemoto, Kenji
    Uchino, Junji
    Morozumi, Nobutoshi
    Ishihara, Shinichi
    Minato, Koichi
    Hisada, Takeshi
    [J]. LUNG CANCER, 2018, 126 : 41 - 47
  • [25] Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus
    Isla, D.
    de Castro, J.
    Garcia-Campelo, R.
    Majem, M.
    Vicente, D.
    Juan-Vidal, O.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (07): : 1304 - 1313
  • [26] Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus
    D. Isla
    J. de Castro
    R. García-Campelo
    M. Majem
    D. Vicente
    O. Juan-Vidal
    [J]. Clinical and Translational Oncology, 2021, 23 : 1304 - 1313
  • [27] Treatment of non-small-cell lung cancer
    Lavolé, A
    Blanchon, F
    Breton, JL
    Milleron, B
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2004, 21 (01) : 175 - 178
  • [28] Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
    Jung, Hyun Ae
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    [J]. BIOLOGY-BASEL, 2020, 9 (10): : 1 - 10
  • [29] Mefatinib as first-line treatment of patients with advanced non-small cell lung cancer harboring rare EGFR mutations.
    Wang, Pingli
    Cao, Liming
    Tian, Panwen
    Ren, Shengxiang
    Miao, Liyun
    Zhou, Chengzhi
    Fan, Yun
    Li, Yuping
    Lv, Dongqing
    Zhao, Xin
    Yang, Mei
    Zhu, Chaonan
    Xu, June
    Song, Yong
    Wang, Kai
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Final analysis of erlotinib monotherapy for elderly patients with non-small-cell lung cancer harboring activating EGFR mutations.
    Akiyama, Norimichi
    Inoue, Yusuke
    Inui, Naoki
    Asada, Kazuhiro
    Karayama, Masato
    Matsuda, Hiroyuki
    Yokomura, Koshi
    Koshimizu, Naoki
    Imokawa, Shiro
    Yamada, Takashi
    Shirai, Toshihiro
    Kasamatsu, Norio
    Suda, Takafumi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345